{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:56:32Z","timestamp":1782255392145,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Canberra Private Practice Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD\u2010L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD\u2010L1 positivity to be an adverse survival prognostic factor in MPM. This study aims to further investigate the relationship between PD\u2010L1 expression in mesothelioma tissues and survival outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data of MPM patients from a single institution between 2006 and 2016 were reviewed. Patient's archived tissues were stained with PD\u2010L1 (Clone Ventana SP263). PD\u2010L1 positivity was defined as\u00a0&gt;\u00a01% membranous staining regardless of intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data from fifty eight patients were analyzed. Median age was 73, majority was male (49, 84%) and had ECOG between 0 and 2 (46, 79%). Most common histopathological subtype was epithelioid (42, 72%), 9 (16%) biphasic subtype and 7 (12%) sarcomatoid. Thirty one patients (53%) received best supportive care and twenty seven patients (47%) received chemotherapy or combination treatment. Forty\u2010two patients had positive PD\u2010L1 expression (72.4%). The median survival time for PD\u2010L1 negative group is 15.5 months and 6 months for the positive group. Positive PD\u2010L1 expression is independently correlated with worse prognosis (HR\u00a0=\u00a02.02; 95% CI, 1.005\u20134.057;\n                      <jats:italic>P<\/jats:italic>\n                      \u2010value\u00a0=\u00a00.0484).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis found a higher percentage of MPM patients with positive PD\u2010L1 (&gt;\u00a01%) compared to other studies. Highly positive PD\u2010L1 expression was associated with statistically significantly lower median survival time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.12788","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T10:46:12Z","timestamp":1509705972000},"page":"69-73","source":"Crossref","is-referenced-by-count":40,"title":["PD\u2010L1 expression associated with worse survival outcome in malignant pleural mesothelioma"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-6027","authenticated-orcid":false,"given":"Bella Hai","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology The Canberra Hospital  Garran ACT Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renn","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology The Canberra Hospital  Garran ACT Australia"},{"name":"The Australian National University Medical School  Acton ACT Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Fadia","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology The Canberra Hospital  Garran ACT Australia"},{"name":"The Australian National University Medical School  Acton ACT Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Wang","sequence":"additional","affiliation":[{"name":"Statistical Consulting Unit The Australian National University  Acton ACT Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The Canberra Hospital  Garran ACT Australia"},{"name":"The Australian National University Medical School  Acton ACT Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Australian Mesothelioma Registry 4th Annual Report2014."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13665-013-0045-1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.12.108"},{"issue":"2","key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bille A","year":"2016","journal-title":"J Thorac Oncol"},{"key":"e_1_2_6_7_1","first-page":"14595","article-title":"Clinicopathological and prognostic value of programmed death ligand\u20101 (PD\u2010L1) in renal cell carcinoma: a meta\u2010analysis.","volume":"8","author":"Xu F","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_6_8_1","first-page":"5369","article-title":"Programmed death\u20101 ligand\u20101 (PD\u2010L1) expression is associated with the prognosis of patients with stage II\/III gastric cancer","volume":"35","author":"Tamura T","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1002729"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"issue":"17","key":"e_1_2_6_11_1","first-page":"30460","article-title":"Tumour suppressor microRNAs contribute to the regulation of PD\u2010L1 expression in malignant pleural mesothelioma","volume":"1556","author":"Kao S","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"15","key":"e_1_2_6_12_1","article-title":"Genome\u2010wide copy number abberations in mesothelioma and its correlation with tumour microenvironment including PD\u2010L1 expression","volume":"12","author":"Thapa B","year":"2017","journal-title":"J Thorac Oncol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second\u2010 or third\u2010line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT\u20101501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel A","year":"2017","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_16_1","unstructured":"TherneauTM LumleyT \u201cPackage \u2018survival\u2019.\u201d2017:2.37\u20134."},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD\u20101\/PD\u2010L1 and TLR3 in malignant pleural mesothelioma","volume":"52","author":"Comaz\u2010Lair C","year":"2016","journal-title":"Hum Pathol"},{"issue":"5","key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome\u2010wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa B","year":"2017","journal-title":"J Thorac Oncol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw289"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2017.35.15_suppl.8514","article-title":"Outcomes of anti\u2010PD\u20101 therapy in mesothelioma and correlation with PD\u2010L1 expression","volume":"35","author":"Rivalland G","year":"2017","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.010"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T04:35:57Z","timestamp":1695875757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/ajco.12788"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12788","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732097355.793551914","asserted-by":"object"}]},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,3]]}}}